Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial (Q42699372)

From Wikidata

Jump to navigation Jump to search

scientific article published on 23 October 2017

Language	Label	Description	Also known as
English	Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial	scientific article published on 23 October 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

phase II clinical trial

0 references

multicenter clinical trial

0 references

Catherine Lombard-Bohas

12

object named as

Catherine Lombard-Bohas

0 references

object named as

Piero Ferolla

1

0 references

object named as

Marcello Tiseo

15

0 references

Henning Grønbæk

object named as

Henning Grønbæk

11

0 references

Alfredo Berruti

8

object named as

Alfredo Berruti

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Vincenzo Minotti

14

object named as

Vincenzo Minotti

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

author name string

Maria Pia Brizzi

2

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Tim Meyer

3

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Wasat Mansoor

4

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Julien Mazieres

5

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Christine Do Cao

6

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Hervé Léna

7

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Vincenzo Damiano

9

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Wieneke Buikhuisen

10

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Catherine Lombard-Bohas

12

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Christian Grohé

13

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Javier De Castro

16

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Nicholas Reed

17

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Gabriella Gislimberti

18

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Neha Singh

19

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Miona Stankovic

20

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Kjell Öberg

21

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Eric Baudin

22

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

publication date

23 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930681-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930681-2

7 January 2021

based on heuristic

inferred from DOI database lookup

ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930681-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930681-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930681-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930681-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930681-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930681-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930681-2

7 January 2021

based on heuristic

inferred from DOI database lookup

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930681-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930681-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of temozolomide in patients with metastatic bronchial carcinoids

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930681-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of PRRT in advanced bronchopulmonary carcinoid

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930681-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930681-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930681-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930681-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bronchial and Thymic Carcinoid Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930681-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930681-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930681-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930681-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(17)30681-2

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42699372&oldid=1966301140"